Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00639
|
|||||
Drug Name |
Lithocholate
|
|||||
Synonyms |
(3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; 3-alpha-Hydroxycholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3alpha-Hydroxy-5beta-cholanate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholanoic acid; 3alpha-Hydroxycholanic acid; 434-13-9; 5-beta-Cholanic acid, 3-alpha-hydroxy-; 5beta-Cholanic acid-3alpha-ol; Bevacizumab + Trastuzumab; CCRIS 363; Lithocholic acid; Lithocolic acid; NCI-C03861; UNII-5QU0I8393U
|
|||||
Drug Type |
Small molecular drug
|
|||||
Structure |
|
![]() |
||||
3D MOL | 2D MOL | |||||
Formula |
C24H40O3
|
|||||
Canonical SMILES |
CC(CCC(=O)O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C
|
|||||
InChI |
InChI=1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1
|
|||||
InChIKey |
SMEROWZSTRWXGI-HVATVPOCSA-N
|
|||||
CAS Number |
CAS 434-13-9
|
|||||
Pharmaceutical Properties | Molecular Weight | 376.6 | Topological Polar Surface Area | 57.5 | ||
Heavy Atom Count | 27 | Rotatable Bond Count | 4 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 3 | |||
XLogP |
6.3
|
|||||
PubChem CID | ||||||
PubChem SID |
10321189
, 103542513
, 103913669
, 104056263
, 104321848
, 111677824
, 11433255
, 11434447
, 11466824
, 11467944
, 11486607
, 14779920
, 16088120
, 17389842
, 22391566
, 24896429
, 26752953
, 26752955
, 29204337
, 29228460
, 3139760
, 46488057
, 47794598
, 48317958
, 48317959
, 48393480
, 48393481
, 48413943
, 48423616
, 48425248
, 49698644
, 49854342
, 50105564
, 519980
, 53789669
, 56463230
, 57325857
, 618557
, 6705
, 76372942
, 7850891
, 8142488
, 8145633
, 8157150
, 85195409
, 87572051
, 88837632
, 92125898
, 92297863
, 93167072
|
|||||
ChEBI ID |
ChEBI:16325
|
|||||
TTD Drug ID |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.